Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | PTCy in unrelated and haploidentical donor alloHSCT in CML

Guillermo Ortí • 21 Mar 2022
EBMT 2022
Chronic Myeloid Leukemia Leukemia Cyclophosphamide

Guillermo Ortí, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, outlines the rationale and design of a retrospective study exploring the outcomes of patients with chronic myeloid leukemia (CML) undergoing unrelated and haploidentical donor allogeneic hematopoietic stem cell transplantation (alloHSCT) with post-transplant cyclophosphamide (PTCy) prophylaxis compared to a historical cohort of patients who have received unrelated donor alloHSCT with calcineurin inhibitor prophylaxis. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from Guillermo Ortí

Expert recommendations on the management of ruxolitinib-refractory GvHD
2:01
Expert recommendations on the management of ruxolitinib-refractory GvHD
Guillermo Ortí • 23 Mar 2026
Emerging therapeutic approaches showing promise for the management of GvHD
2:14
Emerging therapeutic approaches showing promise for the management of GvHD
Guillermo Ortí • 23 Mar 2026
Emerging therapeutic approaches for TKI-resistant CML
1:39
Emerging therapeutic approaches for TKI-resistant CML
Guillermo Ortí • 21 Mar 2022
Latest advances in BP-MPNs
1:08
Latest advances in BP-MPNs
Guillermo Ortí • 21 Mar 2022

Related Videos

Precision intervention strategies in clonal hematopoiesis and CCUS
11:48
Precision intervention strategies in clonal hematopoiesis and CCUS
Kelly Bolton • 3 Oct 2026
Response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusions
11:38
Response criteria for myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase fusions
William Shomali • 3 Oct 2026
Revising response criteria for CMML and MDS/MPN overlap syndromes
12:28
Revising response criteria for CMML and MDS/MPN overlap syndromes
Somedeb Ball • 3 Oct 2026
JAK inhibitors and emerging therapies for MDS/MPN overlap syndromes
9:51
JAK inhibitors and emerging therapies for MDS/MPN overlap syndromes
Abdulraheem Yacoub • 3 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals